SCHEMBL22979535

SCHEMBL22979535

CCn1cc(C(=O)NN)cn1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
MAPT P10636 4/20 0.57
CYP2C19 P33261 1/20 0.57
GFER P55789 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HPGD P15428 2/20 0.55
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 5/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
GSK3B P49841 1/20 0.43
DYRK1A Q13627 1/20 0.43
KLKB1 P03952 1/20 0.42
KDM1A O60341 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25153637 0.86 MAPT (0.57) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL25153635 0.85 MAPT (0.53) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL17663701 0.84 LMNA (0.60) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL13572914 0.83 LMNA (0.56) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL1001641 0.81 L3MBTL1 (0.51) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL24568613 0.81 LMNA (0.53) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL7318801 0.81 L3MBTL1 (0.53) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL31679685 0.81 L3MBTL1 (0.47) LMNAMAPTCYP2C19GFERNPSR1
Hydrochloric Acid SCHEMBL29078120 0.80 L3MBTL1 (0.50) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL12159798 0.79 L3MBTL1 (0.53) LMNAMAPTCYP2C19GFERNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023164235-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 LMNA 2937/4885MAPT 4047/4885CYP2C19 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.